SRSF11

Across TCGA pan-cancer cohorts, SRSF11 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SRSF11 data layer compared with 28 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SRSF11 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SRSF11 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where SRSF11 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	1.000	0.268	.003	9	view →
LUAD	DFS	Tertile	II,III,IV	0.964	0.762	.020	9	view →
PDAC	DFS	Median	II,III,IV	0.875	0.681	.006	6	view →
LSCC	DFS	Median	II,III,IV	0.814	0.580	.023	5	view →
UCEC	DFS	Median	All	1.000	0.936	.023	4	view →
HNSC	DFS	Quartile	IV	0.741	0.936	.028	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SRSF11–CCRCC (DFS)

Open the CCRCC breakdown →